3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
12
aldesleukin
9
fludarabine
8
fludarabine phosphate
7
pembrolizumab
6
Ipilimumab
5
Interleukin-2
5
Nivolumab
4
dabrafenib
2
Vemurafenib
2
Biopsy
2
Aminolevulinic Acid
2
varlilumab
1
trametinib
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
glembatumumab vedotin
1
eprenetapopt
1
epacadostat
1
encorafenib
1
cemiplimab
1
cabozantinib
1
binimetinib
1
bempegaldesleukin
1
abobotulinumtoxinA
1
X-Rays
1
Tranexamic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Skin Neoplasms
×
Interleukins
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts